OpGen to Provide Business Update and Financial Results for the Third Quarter 2020

Rhea-AI Summary

OpGen, Inc. (NASDAQ: OPGN) will release its third quarter 2020 financial results and provide a business update on November 11, 2020, after U.S. market close. The management team will host a live call at 4:30 p.m. ET to discuss the results. Investors can join via U.S. dial-in at +1 (877) 705 6003 or international dial-in at +1 (201) 493 6725. A replay will be available until November 25, 2020. OpGen focuses on molecular diagnostics for infectious diseases, aiming to improve patient outcomes by addressing multidrug-resistant organisms.

Positive

• Scheduled earnings call on November 11, 2020, may provide positive updates.
• Focus on molecular diagnostics positions the company for future growth.

Negative

• None.

GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 11, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
	U.S. Dial-in Number:	+1 (877) 705 6003
	International Dial-in Number:	+1 (201) 493 6725
	Webcast:	http://public.viavid.com/index.php?id=142176
	Conference ID:	13712431
Replay Details
	U.S. Dial-in Number:	+1 (844) 512 2921
	International Dial-in Number:	+1 (412) 317 6671
	Replay PIN:	13712431

Following the conclusion of the conference call, a replay will be available through November 25, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Megan Paul
Edison Group
mpaul@edisongroup.com

FAQ

When will OpGen report its Q3 2020 financial results?

OpGen will report its Q3 2020 financial results on November 11, 2020.

What time is the OpGen earnings call?

The OpGen earnings call is scheduled for 4:30 p.m. ET on November 11, 2020.

How can I access the OpGen earnings call?

The earnings call can be accessed via U.S. dial-in at +1 (877) 705 6003 or international dial-in at +1 (201) 493 6725.

What is OpGen's focus in the medical field?

OpGen focuses on molecular diagnostics to combat infectious diseases and multidrug-resistant organisms.